|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy of tolvaptan in patients with refractory ascites in a clinical setting显示文摘AIM: To elucidate the efficacies of tolvaptan(TLV) as a treatment for refractory ascites compared with conventional treatment. METHODS: We retrospectively enrolled 120 refractory ascites patients between January 1, 2009 and September 31, 2014. Sixty patients were treated with oral TLV at a starting dose of 3.75 mg/d in addition to sodium restriction(> 7 g/d), albumin infusion(10-20 g/wk), and standard diuretic therapy(20-60 mg/d furosemide and 25-50 mg/d spironolactone) and 60 patients with large volume paracentesis in addition to sodium restriction(less than 7 g/d), albumin infusion(10-20 g/wk), and standard diuretic therapy(20-120 mg/d furosemide and 25-150 mg/d spironolactone). Patient demographics and laboratory data, including liver function, were not matched due to the small number of patients. Continuous variables were analyzed by unpaired t-test or paired t-test. Fisher's exact test was applied in cases comparing two nominal variables. We analyzed factors affecting clinical outcomes using receiver operating characteristic curves and multivariate regression analysis. We also used multivariate Cox's proportional hazard regression analysis to elucidate the risk factors that contributed to the increased incidence of ascites.RESULTS: TLV was effective in 38(63.3%) patients. The best cut-off values for urine output and reduced urine osmolality as measures of refractory ascites improvement were > 1800 mL within the first 24 h and > 30%, respectively. Multivariate regression analysis indicated that > 25% reduced urine osmolality [odds ratio(OR) = 20.7; P < 0.01] and positive hepatitis C viral antibodies(OR = 5.93; P = 0.05) were positively correlated with an improvement of refractory ascites, while the total bilirubin level per 1.0 mg/dL(OR = 0.57;P = 0.02) was negatively correlated with improvement. In comparing the TLV group and controls, only the serum sodium level was significantly lower in the TLV group(133 mE q/L vs 136 mE q/L; P = 0.02). However, there were no significant differences in the other parameters between the two groups. The cumulative incidence rate was significantly higher in the control group with a median incidence time of 30 d in the TLV group and 20 d in the control group(P = 0.01). Cox hazard proportional multivariate analysis indicated that the use of TLV(OR = 0.58; P < 0.01), uncontrolled liver neoplasms(OR = 1.92; P < 0.01), total bilirubin level per 1.0 mg/dL(OR = 1.10; P < 0.01), and higher sodium level per 1.0 m Eq/L(OR = 0.94; P < 0.01) were independent factors that contributed to incidence. CONCLUSION: Administration of TLV results in better control of refractory ascites and reduced the incidence of additional invasive procedures or hospitalization compared with conventional ascites treatments. | Takamasa Ohki Koki Sato Tomoharu Yamada Mari Yamagami Daisaku Ito Koki Kawanishi Kentaro Kojima Michiharu Seki Nobuo Toda Kazumi Tagawa | 2015 | World Journal of Hepatology2015，7，12： | 4 |
| 2 | Methotrexate-Related Epstein-Barr Virus (EBV)-Associated Lymphoproliferative Disorder—So-Called “Hodgkin-Like Lesion”—of the Oral Cavity in a Patient with Rheumatoid Arthritis显示文摘 | Kentaro Kikuchi Yuji Miyazaki Akio Tanaka Hisao Shigematu Masaru Kojima Hideaki Sakashita Kaoru Kusama | 2010 | Head and Neck Pathology2010，，4： | 2 |
| 3 | Detection of Ectopic Ureteral Insertion to Vagina With Hypoplastic Ectopic Kidney by Three-Dimensional Computed Tomography显示文摘 | Shoichiro Iwatsuki Yoshiyuki Kojima Makoto Imura Kentaro Mizuno Kenjiro Kohri Yutaro Hayashi | 2009 | Urology2009，，3： | 1 |
| 4 | Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin显示文摘 | Rai Shimoyama Hirofumi Yasui Narikazu Boku Yusuke Onozawa Shuichi Hironaka Akira Fukutomi Kentaro Yamazaki Keisei Taku Takashi Kojima Nozomu Machida Akiko Todaka Hideharu Tomita Takeshi Sakamoto Takahiro Tsushima | 2009 | Gastric Cancer2009，，4： | 1 |
| 5 | Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients显示文摘 | Akihiro Tamiya Kentaro Yamazaki Narikazu Boku Nozomu Machida Takashi Kojima Keisei Taku Hirofumi Yasui Akira Fukutomi Shuichi Hironaka Yusuke Onozawa | 2009 | International Journal of Clinical Oncology2009，，6： | 1 |
| 6 | Expression Profiling of mRNA in Cryptorchid Testes: miR-135a Contributes to the Maintenance of Spermatogonial Stem Cells by Regulating FoxO1显示文摘 | Yoshinobu Moritoki Yutaro Hayashi Kentaro Mizuno Hideyuki Kamisawa Hidenori Nishio Satoshi Kurokawa Shinya Ugawa Yoshiyuki Kojima Kenjiro Kohri | 2013 | The Journal of Urology2013，，： | 1 |
| 7 | Development of a new extracorporeal whole-liver perfusion system显示文摘 | Katsutoshi Naruse Yasuyuki Sakai Lei Guo Takeshi Natori Junichi Shindoh Yasuaki Karasawa Yuhki Iida Kentaro Kojima Kazuya Michishita Masatoshi Makuuchi | 2003 | Journal of Artificial Organs2003，，3： | 1 |
| 8 | MicroRNA-22 and microRNA-140 suppress NF-κB activity by regulating the expression of NF-κB coactivators显示文摘 | Akemi Takata Motoyuki Otsuka Kentaro Kojima Takeshi Yoshikawa Takahiro Kishikawa Haruhiko Yoshida Kazuhiko Koike | 2011 | Biochemical and Biophysical Research Communications2011，，4： | 1 |
| 9 | Functional cell surface expression of Toll-like receptor 9 promotescell proliferation and survival in human hepatocellular carcinomas显示文摘 | Junichiro Tanaka Kazushi Sugimoto Katsuya Shiraki Masahiko Tameda Satoko Kusagawa Keiichiro Nojiri Tetsuya Beppu Kentaro Yoneda Norihiko Yamamoto Kazuhiko Uchida Takahiro Kojima Yoshiyuki Takei | 2010 | International Journal of Oncology2010，，4： | 1 |
| 10 | Long-term physical, hormonal, and sexual outcome of males with disorders of sex development 显示文摘 | Yoshiyuki Kojima Kentaro Mizuno Akihiro Nakane | 2009 | Journal of Pediatric Surgery2009，44，： | 1 |
| 11 | Characterization of the urethral plate and the underlying tis- sue defined by expression of collagen subtypes and microar- chiteeture in hypospadias显示文摘 | Yutaro Hayashi Kentaro Mizuno Yoshiyuki Kojima | 2011 | Int J Urol2011，18，： | 1 |
| 12 | Embolization of Rectal Varices via a Paraumbilical Vein with an Abdominal Wall Approach in a Patient with Massive Ascites显示文摘 | Kenji Ibukuro Kentaro Kojima Ikutaro Kigawa Rei Tanaka Hozumi Fukuda Shoko Abe Kimiko Tobe Kazumi Tagawa | 2009 | Journal of Vascular and Interventional Radiology2009，，9： | 1 |
| 13 | Feasibility of laparoscopic total gastrectomy in overweight patients: Implications of less impact of overweight on laparoscopic versus open approach显示文摘AIM To investigate safety and oncological feasibility of laparoscopic total gastrectomy(LTG) in overweight(OW) patients.METHODS Patients who underwent total gastrectomy(110 laparoscopic, 211 open) for gastric cancer between January 1999 and July 2016 were included. Propensity score matching selected 152 patients(76 laparoscopic, 76 open), which were subsequently divided into the OW(≥ 25) or non-OW(< 25) group by body mass index. Postoperative outcomes of laparoscopic versus open approaches were compared between OW and non-OW groups. RESULTS In the propensity-matched population, baseline characteristics were comparable between the OW and nonOW groups for the laparoscopy and open groups. In the laparoscopy group, operative time was longer(P = 0.01) in the OW group, however, other perioperative results including complication rates were comparable between the non-OW and OW groups. In the open group, number of retrieved lymph nodes were less(P = 0.03) and local complication rate was more frequent(P = 0.03) in the OW group. CONCLUSION LTG in OW patients remains technically challenging but can be performed safely. Our findings imply that OW has a lesser effect on the laparoscopic versus open approach to total gastrectomy. | Masatoshi Nakagawa Kazuyuki Kojima Mikito Inokuchi Kenta Kobayashi Toshiro Tanioka Keisuke Okuno Kentaro Gokita | 2018 | World Journal of Clinical Cases2018，6，16： | 0 |
| 14 | GATA4 mutations are uncommon in patients with 46,XY disorders of sex development without heart anomaly显示文摘 | Maki Igarashi Kentaro Mizuno Masafumi Kon Satoshi Narumi Yoshiyuki Kojima Yutaro Hayashi Tsutomu Ogata Maki Fukami | 2018 | Asian Journal of Andrology2018，20，6： | 0 |
| 15 | Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis显示文摘BACKGROUND Real-world data on tofacitinib(TOF)covering a period of more than 1 year for a sufficient number of Asian patients with ulcerative colitis(UC)are scarce.AIM To investigate the long-term efficacy and safety of TOF treatment for UC,including clinical issues.METHODS We performed a retrospective single-center observational analysis of 111 UC patients administered TOF at Hyogo Medical University as a tertiary inflammatory bowel disease center.All consecutive UC patients who received TOF between May 2018 and February 2020 were enrolled.Patients were followed up until August 2020.The primary outcome was the clinical response rate at week 8.Secondary outcomes included clinical remission at week 8,cumulative persistence rate of TOF administration,colectomy-free survival,relapse after tapering of TOF and predictors of clinical response at week 8 and week 48.RESULTS The clinical response and remission rates were 66.3%and 50.5%at week 8,and 47.1%and 43.5%at week 48,respectively.The overall cumulative clinical remission rate was 61.7%at week 48 and history of anti-tumor necrosis factor-alpha(TNF-α)agents use had no influence(P=0.25).The cumulative TOF persistence rate at week 48 was significantly lower in patients without clinical remission than in those with remission at week 8(30.9%vs 88.1%;P<0.001).Baseline partial Mayo Score was significantly lower in responders vs non-responders at week 8(odds ratio:0.61,95%confidence interval:0.45-0.82,P=0.001).Relapse occurred in 45.7%of patients after TOF tapering,and 85.7%of patients responded within 4 wk after re-increase.All 6 patients with herpes zoster(HZ)developed the infection after achieving remission by TOF.CONCLUSION TOF was more effective in UC patients with mild activity at baseline and its efficacy was not affected by previous treatment with anti-TNF-αagents.Most relapsed patients responded again after re-increase of TOF and nearly half relapsed after tapering off TOF.Special attention is needed for tapering and HZ. | Kentaro Kojima Kenji Watanabe Mikio Kawai Soichi Yagi Koji Kaku Maiko Ikenouchi Toshiyuki Sato Koji Kamikozuru Yoko Yokoyama Tetsuya Takagawa Masahito Shimizu Shinichiro Shinzaki | 2024 | World Journal of Gastroenterology2024，30，13： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员